Ernexa Therapeutics (ERNAW) Change in Accured Expenses (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Change in Accured Expenses data on file, last reported at $93000.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 194.9% year-over-year to $93000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $251000.0 (up 166.76% YoY) and the FY2025 annual result came in at $60000.0, down 67.21% from the prior year.
• Change in Accured Expenses slipped to $93000.0 in Q1 2026, from $223000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.8 million in Q2 2023 to a low of -$2.5 million in Q4 2023.
• A 5-year average of -$141588.2 and a median of -$112000.0 in 2024 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses slumped 774.26% — and 2025, when it surged 367.86%.
• Tracing ERNAW's Change in Accured Expenses over 5 years: stood at -$495000.0 in 2022, then slumped by 410.91% to -$2.5 million in 2023, then surged by 102.77% to $70000.0 in 2024, then jumped by 218.57% to $223000.0 in 2025, then slumped by 58.3% to $93000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $93000.0 (Q1 2026), $223000.0 (Q4 2025), and $300000.0 (Q3 2025), per Business Quant data.